Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH)...
12 Marzo 2018 - 5:00AM
Business Wire
- Educational webinar to be held on Wednesday,
March 28th at 8:00 a.m. EDT -
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced that it will
host an educational webinar on pulmonary arterial hypertension
(PAH) and the Company’s Phase 2 clinical trial of sotatercept in
patients with PAH. The webinar will be led by Acceleron’s senior
management team and PAH disease experts, Aaron B. Waxman, M.D.,
Ph.D., and David Badesch, M.D. The webinar is scheduled for
Wednesday, March 28, 2018 at 8:00 a.m. EDT.
Dr. Waxman is the director of the Pulmonary Vascular Disease
Program at Brigham and Women’s Hospital (BWH). He is also an
associate professor of medicine at Harvard Medical School. His
clinical interests include PAH, right heart failure, thromboembolic
disease and pulmonary vascular disease. He has authored over 110
peer-reviewed publications and has research funding from the
National Institutes of Health and the National Heart, Lung, and
Blood Institute. Dr. Waxman will present a PAH disease overview and
provide an update on the current treatment landscape.
Dr. Badesch is the clinical director of the Pulmonary
Hypertension Center at the University of Colorado Hospital. He is
also a professor of Divisions of Pulmonary Sciences and Critical
Care Medicine and Cardiology at the University of Colorado Anschutz
Medical Campus. Dr. Badesch is actively involved in furthering PAH
research, treatment options and disease awareness. He has authored
over 137 peer-reviewed publications and previously served as the
Chair of the Pulmonary Circulation Assembly of the American
Thoracic Society, and the Scientific Leadership Council of the
Pulmonary Hypertension Association. Dr. Badesch, the Sotatercept
Steering Committee Chair, will present the Phase 2 study
design.
Webinar DetailsDate: Wednesday, March 28, 2018Time: 8:00
a.m. EDT
Participants can access the live conference call by
dialing 877-312-5848 (domestic) or 253-237-1155
(international) and refer to the “Acceleron Sotatercept in PAH
Webinar.”
The live webinar can be accessed on the Investors page of the
Company's website at www.acceleronpharma.com.
A replay of the webinar will be available approximately two
hours after the event on the Acceleron website.
About Sotatercept
Sotatercept is an activin receptor type IIA fusion protein that
acts as a ligand trap for members in the transforming growth
factor-beta superfamily involved in remodeling a variety of
different tissues, including the vasculature and fibrosis. In
multiple preclinical studies in PAH, sotatercept decreased vessel
muscularization, improved pulmonary arterial pressures, and
decreased indicators of right heart failure.
About Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) is a rare and chronic,
rapidly progressing disorder characterized by the constriction of
small pulmonary arteries and elevated blood pressure in the
pulmonary circulation. PAH results in significant and progressive
strain on the right side of the heart, often leading to limited
physical activity, heart failure, and reduced life expectancy. The
5-year survival rate for patients with PAH is approximately 57%.
Available therapies generally act by promoting the dilation of
pulmonary vessels without addressing the underlying cause of the
disease. As a result, PAH often progresses rapidly for many
patients despite standard of care treatment. A growing body of
research has implicated imbalances in BMP and TGF-beta signaling as
a primary driver of PAH in familial, idiopathic and acquired forms
of the disease.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a planned Phase 2 trial of sotatercept in pulmonary
arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180312005395/en/
IRC for Acceleron Pharma Inc.Todd James, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024